$JBIO News

Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $45

Jade Biosciences: Strong Early Signal, But Still A Wait For Proof

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Why Is Jade Biosciences Stock Trading Lower On Monday?

BTIG Maintains Buy on Jade Biosciences, Raises Price Target to $74

HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $55

jade Biosciences Announces Interim Results From Its Phase 1 Trial Evaluating JADE101, A Novel, Investigational AntI-A Proliferation-Inducing Ligand Monoclonal Antibody In Development For The Treatment Of Immunoglobulin A Nephropathyl; JADE101 Showed Favorable Safety Profile And Well-Tolerated Across All Evaluated Subcutaneous Dose Levels

Jade Biosciences To Present Phase 1 JADE101 Data In Conference Call On June 1, 2026 At 8:00 a.m. ET

BTIG Reiterates Buy on Jade Biosciences, Maintains $39 Price Target

Jade Biosciences Doses First Patient In Phase 1 Clinical Study Of JADE201; Anticipates Interim First-In-Human Data Next Year

Jade Biosciences Files Prospectus Related To Resale Of Up To 39,542,339 Shares By Selling Stockholders

Guggenheim Maintains Buy on Jade Biosciences, Raises Price Target to $32

Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $34

Jade Biosciences May Offer And Sell Up To $200M Common Stock Under Sales Agreement With Jefferies

Jade Biosciences Files Prospectus To Offer And Sell Up To $600M Of Securities

Jade Biosciences Registration Statement Covers Resale Of Up To 39,542,339 Shares Of Common Stock By The Selling Stockholders

Jade Biosciences Q1 EPS $(0.57) Misses $(0.51) Estimate

Jade Biosciences shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $35 to $45.

Jade Biosciences shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $35 to $45.

HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $45